20 March 2023
EMA/112293/2023
EMEA/H/C/001119

Public statement

Nevirapine Teva (nevirapine)

Withdrawal of the marketing authorisation in the European Union

On 6 March 2023 the European Commission withdrew the marketing authorisation for Nevirapine Teva (nevirapine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Nevirapine Teva was granted marketing authorisation in the EU on 30 November 2009 for treatment of HIV-1 infection. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Nevirapine Teva is a generic medicine of Viramune.

The European Public Assessment Report (EPAR) for Nevirapine Teva will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union